17 Capital Partners’s Neurocrine Biosciences NBIX Stock Holding History

17 Capital Partners’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$604K	Buy	4,585 +250	+6%	+$33.2K	0.31%	107
2025 Q4	$615K	Buy	4,335 +770	+22%	+$112K	0.32%	97
2025 Q3	$500K	Hold	3,565	–	–	0.27%	104
2025 Q2	$448K	Buy	3,565 +650	+22%	+$74.5K	0.26%	102
2025 Q1	$322K	Buy	2,915 +1,205	+70%	+$153K	0.21%	119
2024 Q4	$233K	Sell	1,710 -4,136	-71%	-$512K	0.15%	123
2024 Q3	$674K	Buy	5,846 +2,881	+97%	+$395K	0.44%	72
2024 Q2	$408K	Buy	+2,965	New	+$407K	0.29%	93

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

17 Capital Partners's NBIX Position: Q1 2026 in Review

17 Capital Partners increased its Neurocrine Biosciences (NBIX) stake by 5.8% in Q1 2026, buying an estimated $33.2K and bringing the position to 4,585 shares worth $604K. The position accounts for 0.31% of the portfolio, ranked #107.

17 Capital Partners first reported a position in NBIX in Q2 2024 and has held it in 8 quarters since. The position peaked at $674K in Q3 2024. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

17 Capital Partners held 4,585 shares of Neurocrine Biosciences worth $604K as of Q1 2026.
17 Capital Partners bought 250 Neurocrine Biosciences shares in Q1 2026, an estimated $33.2K.
Neurocrine Biosciences made up 0.31% of 17 Capital Partners's portfolio in Q1 2026, its #107 holding.
17 Capital Partners first reported a position in Neurocrine Biosciences in Q2 2024 and has held it in 8 quarters since.
17 Capital Partners's Neurocrine Biosciences position peaked at $674K in Q3 2024.
695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on 17 Capital Partners's 13F filing for Q1 2026, filed 13 May 2026.